The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global APOL1 Mediated Kidney Disease Market Research Report 2025
Synopsis
APOL1 gene is a member of APOL gene family, which plays an important role in innate immunity, which is our body’s built-in defense system to fight threats. Some variations in APOL1 gene cause damage to parts within the kidney. Damage to parts that filter blood can lead to severe kidney disease or ultimately kidney failure. An example of such an indication is focal segmental glomerulosclerosis (FSGS), which is a type of kidney disease that can be caused by APOL1 gene variations.
The global APOL1 Mediated Kidney Disease market was valued at US$ 812 million in 2023 and is anticipated to reach US$ 1218.5 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for APOL1 Mediated Kidney Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding APOL1 Mediated Kidney Disease.
Report Scope
The APOL1 Mediated Kidney Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global APOL1 Mediated Kidney Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the APOL1 Mediated Kidney Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Vertex Pharmaceuticals
Ionis Pharmaceuticals
Travere Therapeutics
ChemoCentryx
ZyVersa Therapeutics
GlaxoSmithKline
Novartis
Teva Pharmaceuticals
Segment by Type
Small Molecule
Gene Modification
Nucleic Acid Therapies
Others
Segment by Application
Chronic Kidney Disease
End Stage Kidney Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of APOL1 Mediated Kidney Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
APOL1 gene is a member of APOL gene family, which plays an important role in innate immunity, which is our body’s built-in defense system to fight threats. Some variations in APOL1 gene cause damage to parts within the kidney. Damage to parts that filter blood can lead to severe kidney disease or ultimately kidney failure. An example of such an indication is focal segmental glomerulosclerosis (FSGS), which is a type of kidney disease that can be caused by APOL1 gene variations.
The global APOL1 Mediated Kidney Disease market was valued at US$ 812 million in 2023 and is anticipated to reach US$ 1218.5 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for APOL1 Mediated Kidney Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding APOL1 Mediated Kidney Disease.
Report Scope
The APOL1 Mediated Kidney Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global APOL1 Mediated Kidney Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the APOL1 Mediated Kidney Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Vertex Pharmaceuticals
Ionis Pharmaceuticals
Travere Therapeutics
ChemoCentryx
ZyVersa Therapeutics
GlaxoSmithKline
Novartis
Teva Pharmaceuticals
Segment by Type
Small Molecule
Gene Modification
Nucleic Acid Therapies
Others
Segment by Application
Chronic Kidney Disease
End Stage Kidney Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of APOL1 Mediated Kidney Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Small Molecule
1.2.3 Gene Modification
1.2.4 Nucleic Acid Therapies
1.2.5 Others
1.3 Market by Application
1.3.1 Global APOL1 Mediated Kidney Disease Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Chronic Kidney Disease
1.3.3 End Stage Kidney Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global APOL1 Mediated Kidney Disease Market Perspective (2019-2030)
2.2 APOL1 Mediated Kidney Disease Growth Trends by Region
2.2.1 Global APOL1 Mediated Kidney Disease Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 APOL1 Mediated Kidney Disease Historic Market Size by Region (2019-2024)
2.2.3 APOL1 Mediated Kidney Disease Forecasted Market Size by Region (2025-2030)
2.3 APOL1 Mediated Kidney Disease Market Dynamics
2.3.1 APOL1 Mediated Kidney Disease Industry Trends
2.3.2 APOL1 Mediated Kidney Disease Market Drivers
2.3.3 APOL1 Mediated Kidney Disease Market Challenges
2.3.4 APOL1 Mediated Kidney Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue
3.1.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue (2019-2024)
3.1.2 Global APOL1 Mediated Kidney Disease Revenue Market Share by Players (2019-2024)
3.2 Global APOL1 Mediated Kidney Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by APOL1 Mediated Kidney Disease Revenue
3.4 Global APOL1 Mediated Kidney Disease Market Concentration Ratio
3.4.1 Global APOL1 Mediated Kidney Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by APOL1 Mediated Kidney Disease Revenue in 2023
3.5 APOL1 Mediated Kidney Disease Key Players Head office and Area Served
3.6 Key Players APOL1 Mediated Kidney Disease Product Solution and Service
3.7 Date of Enter into APOL1 Mediated Kidney Disease Market
3.8 Mergers & Acquisitions, Expansion Plans
4 APOL1 Mediated Kidney Disease Breakdown Data by Type
4.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Type (2019-2024)
4.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2025-2030)
5 APOL1 Mediated Kidney Disease Breakdown Data by Application
5.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Application (2019-2024)
5.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America APOL1 Mediated Kidney Disease Market Size (2019-2030)
6.2 North America APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America APOL1 Mediated Kidney Disease Market Size by Country (2019-2024)
6.4 North America APOL1 Mediated Kidney Disease Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe APOL1 Mediated Kidney Disease Market Size (2019-2030)
7.2 Europe APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe APOL1 Mediated Kidney Disease Market Size by Country (2019-2024)
7.4 Europe APOL1 Mediated Kidney Disease Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size (2019-2030)
8.2 Asia-Pacific APOL1 Mediated Kidney Disease Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2019-2024)
8.4 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America APOL1 Mediated Kidney Disease Market Size (2019-2030)
9.2 Latin America APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America APOL1 Mediated Kidney Disease Market Size by Country (2019-2024)
9.4 Latin America APOL1 Mediated Kidney Disease Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size (2019-2030)
10.2 Middle East & Africa APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2019-2024)
10.4 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Detail
11.1.2 Vertex Pharmaceuticals Business Overview
11.1.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.1.4 Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2019-2024)
11.1.5 Vertex Pharmaceuticals Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Detail
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.2.4 Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2019-2024)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Travere Therapeutics
11.3.1 Travere Therapeutics Company Detail
11.3.2 Travere Therapeutics Business Overview
11.3.3 Travere Therapeutics APOL1 Mediated Kidney Disease Introduction
11.3.4 Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2019-2024)
11.3.5 Travere Therapeutics Recent Development
11.4 ChemoCentryx
11.4.1 ChemoCentryx Company Detail
11.4.2 ChemoCentryx Business Overview
11.4.3 ChemoCentryx APOL1 Mediated Kidney Disease Introduction
11.4.4 ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2019-2024)
11.4.5 ChemoCentryx Recent Development
11.5 ZyVersa Therapeutics
11.5.1 ZyVersa Therapeutics Company Detail
11.5.2 ZyVersa Therapeutics Business Overview
11.5.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Introduction
11.5.4 ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2019-2024)
11.5.5 ZyVersa Therapeutics Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Introduction
11.6.4 GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2019-2024)
11.6.5 GlaxoSmithKline Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis APOL1 Mediated Kidney Disease Introduction
11.7.4 Novartis Revenue in APOL1 Mediated Kidney Disease Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Detail
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.8.4 Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2019-2024)
11.8.5 Teva Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Small Molecule
Table 3. Key Players of Gene Modification
Table 4. Key Players of Nucleic Acid Therapies
Table 5. Key Players of Others
Table 6. Global APOL1 Mediated Kidney Disease Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global APOL1 Mediated Kidney Disease Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global APOL1 Mediated Kidney Disease Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global APOL1 Mediated Kidney Disease Market Share by Region (2019-2024)
Table 10. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global APOL1 Mediated Kidney Disease Market Share by Region (2025-2030)
Table 12. APOL1 Mediated Kidney Disease Market Trends
Table 13. APOL1 Mediated Kidney Disease Market Drivers
Table 14. APOL1 Mediated Kidney Disease Market Challenges
Table 15. APOL1 Mediated Kidney Disease Market Restraints
Table 16. Global APOL1 Mediated Kidney Disease Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global APOL1 Mediated Kidney Disease Market Share by Players (2019-2024)
Table 18. Global Top APOL1 Mediated Kidney Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in APOL1 Mediated Kidney Disease as of 2023)
Table 19. Ranking of Global Top APOL1 Mediated Kidney Disease Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by APOL1 Mediated Kidney Disease Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players APOL1 Mediated Kidney Disease Product Solution and Service
Table 23. Date of Enter into APOL1 Mediated Kidney Disease Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global APOL1 Mediated Kidney Disease Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2019-2024)
Table 27. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2025-2030)
Table 29. Global APOL1 Mediated Kidney Disease Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global APOL1 Mediated Kidney Disease Revenue Market Share by Application (2019-2024)
Table 31. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global APOL1 Mediated Kidney Disease Revenue Market Share by Application (2025-2030)
Table 33. North America APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America APOL1 Mediated Kidney Disease Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America APOL1 Mediated Kidney Disease Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe APOL1 Mediated Kidney Disease Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe APOL1 Mediated Kidney Disease Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific APOL1 Mediated Kidney Disease Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America APOL1 Mediated Kidney Disease Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America APOL1 Mediated Kidney Disease Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2025-2030) & (US$ Million)
Table 48. Vertex Pharmaceuticals Company Detail
Table 49. Vertex Pharmaceuticals Business Overview
Table 50. Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product
Table 51. Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2019-2024) & (US$ Million)
Table 52. Vertex Pharmaceuticals Recent Development
Table 53. Ionis Pharmaceuticals Company Detail
Table 54. Ionis Pharmaceuticals Business Overview
Table 55. Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product
Table 56. Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2019-2024) & (US$ Million)
Table 57. Ionis Pharmaceuticals Recent Development
Table 58. Travere Therapeutics Company Detail
Table 59. Travere Therapeutics Business Overview
Table 60. Travere Therapeutics APOL1 Mediated Kidney Disease Product
Table 61. Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2019-2024) & (US$ Million)
Table 62. Travere Therapeutics Recent Development
Table 63. ChemoCentryx Company Detail
Table 64. ChemoCentryx Business Overview
Table 65. ChemoCentryx APOL1 Mediated Kidney Disease Product
Table 66. ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2019-2024) & (US$ Million)
Table 67. ChemoCentryx Recent Development
Table 68. ZyVersa Therapeutics Company Detail
Table 69. ZyVersa Therapeutics Business Overview
Table 70. ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product
Table 71. ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2019-2024) & (US$ Million)
Table 72. ZyVersa Therapeutics Recent Development
Table 73. GlaxoSmithKline Company Detail
Table 74. GlaxoSmithKline Business Overview
Table 75. GlaxoSmithKline APOL1 Mediated Kidney Disease Product
Table 76. GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2019-2024) & (US$ Million)
Table 77. GlaxoSmithKline Recent Development
Table 78. Novartis Company Detail
Table 79. Novartis Business Overview
Table 80. Novartis APOL1 Mediated Kidney Disease Product
Table 81. Novartis Revenue in APOL1 Mediated Kidney Disease Business (2019-2024) & (US$ Million)
Table 82. Novartis Recent Development
Table 83. Teva Pharmaceuticals Company Detail
Table 84. Teva Pharmaceuticals Business Overview
Table 85. Teva Pharmaceuticals APOL1 Mediated Kidney Disease Product
Table 86. Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2019-2024) & (US$ Million)
Table 87. Teva Pharmaceuticals Recent Development
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Global APOL1 Mediated Kidney Disease Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global APOL1 Mediated Kidney Disease Market Share by Type: 2023 VS 2030
Figure 3. Small Molecule Features
Figure 4. Gene Modification Features
Figure 5. Nucleic Acid Therapies Features
Figure 6. Others Features
Figure 7. Global APOL1 Mediated Kidney Disease Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global APOL1 Mediated Kidney Disease Market Share by Application: 2023 VS 2030
Figure 9. Chronic Kidney Disease Case Studies
Figure 10. End Stage Kidney Disease Case Studies
Figure 11. APOL1 Mediated Kidney Disease Report Years Considered
Figure 12. Global APOL1 Mediated Kidney Disease Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global APOL1 Mediated Kidney Disease Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global APOL1 Mediated Kidney Disease Market Share by Region: 2023 VS 2030
Figure 15. Global APOL1 Mediated Kidney Disease Market Share by Players in 2023
Figure 16. Global Top APOL1 Mediated Kidney Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in APOL1 Mediated Kidney Disease as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by APOL1 Mediated Kidney Disease Revenue in 2023
Figure 18. North America APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America APOL1 Mediated Kidney Disease Market Share by Country (2019-2030)
Figure 20. United States APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe APOL1 Mediated Kidney Disease Market Share by Country (2019-2030)
Figure 24. Germany APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific APOL1 Mediated Kidney Disease Market Share by Region (2019-2030)
Figure 32. China APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America APOL1 Mediated Kidney Disease Market Share by Country (2019-2030)
Figure 40. Mexico APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa APOL1 Mediated Kidney Disease Market Share by Country (2019-2030)
Figure 44. Turkey APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia APOL1 Mediated Kidney Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Vertex Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2019-2024)
Figure 47. Ionis Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2019-2024)
Figure 48. Travere Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2019-2024)
Figure 49. ChemoCentryx Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2019-2024)
Figure 50. ZyVersa Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2019-2024)
Figure 51. GlaxoSmithKline Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2019-2024)
Figure 52. Novartis Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2019-2024)
Figure 53. Teva Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
